Detalhe da pesquisa
1.
Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.
N Engl J Med
; 378(25): 2386-2398, 2018 Jun 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-29860938
2.
Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumors.
Invest New Drugs
; 38(2): 433-444, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31028664
3.
Isocitrate dehydrogenase 1 and 2 mutations, 2-hydroxyglutarate levels, and response to standard chemotherapy for patients with newly diagnosed acute myeloid leukemia.
Cancer
; 125(4): 541-549, 2019 02 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30422308
4.
Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia.
Blood
; 130(6): 722-731, 2017 08 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-28588020
5.
IDH2 mutation-induced histone and DNA hypermethylation is progressively reversed by small-molecule inhibition.
Blood
; 125(2): 296-303, 2015 Jan 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-25398940
6.
Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML.
Am J Hematol
; 90(8): 732-6, 2015 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-26016821
7.
Isocitrate dehydrogenase 1 (IDH1) mutation in breast adenocarcinoma is associated with elevated levels of serum and urine 2-hydroxyglutarate.
Oncologist
; 19(6): 602-7, 2014 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-24760710
8.
Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Safety and Clinical Activity in Patients With Advanced Chondrosarcoma.
J Clin Oncol
; 38(15): 1693-1701, 2020 05 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-32208957
9.
Pharmacokinetics, absorption, metabolism, and excretion of [14C]ivosidenib (AG-120) in healthy male subjects.
Cancer Chemother Pharmacol
; 83(5): 837-848, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30758648
10.
Phase 1 Single- and Multiple-Ascending-Dose Randomized Studies of the Safety, Pharmacokinetics, and Pharmacodynamics of AG-348, a First-in-Class Allosteric Activator of Pyruvate Kinase R, in Healthy Volunteers.
Clin Pharmacol Drug Dev
; 8(2): 246-259, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30091852
11.
Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib.
Nat Med
; 24(8): 1167-1177, 2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-30013198
12.
Circulating oncometabolite 2-hydroxyglutarate is a potential surrogate biomarker in patients with isocitrate dehydrogenase-mutant intrahepatic cholangiocarcinoma.
Clin Cancer Res
; 20(7): 1884-90, 2014 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-24478380
13.
Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation.
Science
; 340(6132): 622-6, 2013 May 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-23558173